MedTrace Logo

A Multi-Center Study on the Metoprolol Optimal Dosing Pathway of Metoprolol Application in Chinese Patients With Acute Coronary Syndrome

NCT03413410 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2019-07-19

No results posted yet for this study

Summary

This study is to test the feasibility and tolerability of the metoprolol optimal dosing pathway by observing the percentage of patients achieving target dose followed the pathway on ACS patients during hospitalization.

Conditions

  • ACS - Acute Coronary Syndrome

Interventions

DRUG

Metoprolol

Patients with acute coronary syndrome take metoprolol during hospital and after discharge in the optimal dosing pathway.

Sponsors & Collaborators

  • Yun Dai Chen

    lead OTHER

Principal Investigators

  • Yundai Chen, MD · The General Hospital of PLA

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-01
Primary Completion
2019-07-30
Completion
2020-07-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03413410 on ClinicalTrials.gov